Bacil Pharma Limited is an India-based pharmaceutical company, which is engaged in the business of manufacturing of pharmaceuticals, medicinal chemicals and botanical products. The Company operates as a manufacturer, exporter, supplier and retailer of a range of anti-anxiety medicine, antihistamines, chemical compound, drugs, and herbal tablets and capsules.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-11-08	₹17.04	0.00%	1,401
26-11-06	₹17.04	-4.86%	13,736
26-11-05	₹17.91	+2.64%	15,582
26-11-04	₹17.45	-3.11%	12,484
26-11-03	₹18.01	-4.71%	225

Delayed Quote Bombay S.E.

More quotes

Market Closed - Bombay S.E. 05:02:15 2026-11-08 EST			5-day change	1st Jan Change
17.04 ^INR	0.00%		-9.41%	-52.19%

10-14	Bacil Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
10-08	Bacil Pharma Limited Announces Resignation of Dikshant Singh Panwar as Whole-Time Company Secretary and Compliance Officer, Effective October 08, 2026	CI

Market Cap	245M 2.6M 2.33M 2.13M 1.95M 3.67M 3.78M 25.71M 10.25M 131M 9.77M 9.56M 412M	P/E 2025	66.4x	P/E 2026	43x
Enterprise Value	239M 2.54M 2.28M 2.08M 1.9M 3.58M 3.7M 25.11M 10.01M 127M 9.54M 9.33M 402M	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	36.26%	Yield 2025 *	-	Yield 2026	-

10-14	Bacil Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
10-08	Bacil Pharma Limited Announces Resignation of Dikshant Singh Panwar as Whole-Time Company Secretary and Compliance Officer, Effective October 08, 2026	CI
09-24	Bacil Pharma Limited Approves the Designation Change of Chaitali Kalpataru from Executive Director to Managing Director	CI
08-12	Bacil Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-10	Bacil Pharma Limited Announces Board Resignations, Effective July 9, 2026	CI
05-22	Bacil Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-13	Bacil Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
12-01	Bacil Pharma Limited Announces Resignation of Bhavana Phoolchand Tak as Company Secretary and Compliance Officer, Effective December 1, 2025	CI
11-13	Bacil Pharma Limited Reports Earnings Results for the Second Quarter Ended September 30, 2025	CI
25-08-25	Bacil Pharma Limited Appoints Vivek Mukesh Yadav as Independent Director, Effective August 25, 2025	CI
25-08-12	Bacil Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-07-22	Bacil Pharma Limited Announces Resignation of Prakash Bhoorchand Shah as Director	CI
25-07-16	Bacil Pharma appoints Chaitali Kalpataru Shah as and CFO	RE

1 week	-9.41%
Current month	-9.41%
1 month	-29.62%
3 months	+0.65%
6 months	-70.07%
Current year	-52.19%

Bacil Pharma Limited Stock

Stocks

BACPHAR6

INE711D01018

Pharmaceuticals

Valuation: Bacil Pharma Limited

Chart: Bacil Pharma Limited

Latest news: Bacil Pharma Limited

Quotes and Performance

Price Extremes

Managers and Directors: Bacil Pharma Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	16.81	18.86
1 month	16.81	25.4
Current year	10.65	61.8
1 year	10.65	61.8
3 years	4.68	62.56
5 years	3.67	62.56
10 years	1.57	62.56

Manager	Title	Age	Since
Chaitali Kalpataru Shah CEO	Chief Executive Officer	46	2026-08-24
Dikshant Singh Panwar CMP	Compliance Officer	-	2025-12-18

Director	Title	Age	Since
Chaitali Kalpataru Shah BRD	Director/Board Member	46	2025-07-15
Vivek Mukesh Yadav BRD	Director/Board Member	21	2026-06-29
Omprakash Pyarelal Sonar BRD	Director/Board Member	45	2026-06-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BACIL PHARMA LIMITED	0.00%	-9.41%	-39.49%	+114.61%	2.6M
ELI LILLY AND COMPANY	-0.79%	-4.48%	+46.48%	+118.69%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+48.05%	+83.72%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.92%	+105.10%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+45.42%	+63.89%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+70.06%	+40.55%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.47%	+56.79%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+7.98%	+36.97%	289B
AMGEN INC.	+0.03%	-1.20%	+43.79%	+68.49%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+40.43%	+114.24%	207B
Average	-0.08%	-2.33%	+32.61%	+80.30%	417.97B
Weighted average by Cap.	-0.04%	-1.96%	+42.71%	+86.30%

	2025	2026
Net sales	-	-
Net income	4.04M 42.99K 38.56K 35.24K 32.17K 60.6K 62.51K 425K 169K 2.16M 161K 158K 6.81M	15.56M 165K 148K 136K 124K 233K 241K 1.63M 652K 8.3M 621K 608K 26.2M
Net Debt	-26.93M -287K -257K -235K -214K -404K -417K -2.83M -1.13M -14.37M -1.08M -1.05M -45.37M	-5.68M -60.48K -54.24K -49.57K -45.25K -85.26K -87.95K -598K -238K -3.03M -227K -222K -9.58M